Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Bintrafusp Alfa

            Therapeutic Area: Oncology Product Name: efti

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Immutep

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 01, 2021

            Details:

            The trial will study feasibility, safety & efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), given in combination with Merck's bintrafusp alfa (M7824), Bintrafusp alfa blocks TGF-β and PD-L1, while efti activates antigen presenting cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AB248

            Therapeutic Area: Oncology Product Name: AB248

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Asher Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 26, 2021

            Details:

            ProBioGen to provide cell line development, process development and GMP manufacturing at 1000 L bioreactor scale of Asher's lead immuno-oncology candidate, AB248.